CYP2A5 induction and hepatocellular stress: An adaptive response to perturbations of heme homeostasis

Current Drug Metabolism

Volumn 12, Issue 2, 2011, Pages 186-197

  Kirby, Gordon M ^a   Nichols, Kathleen D ^a   Antenos, Monica ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Bilirubin; CYP2A5; Heme; Induction; Liver injury; Metabolism

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; BILIRUBIN; CYTOCHROME P450 2A5; CYTOCHROME P450 2A6; HEME; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; IMIDAZOLE; NICOTINE; PORPHYRIN; PURINE; PYRAZOLE; PYRIDINE; PYRROLE; PYRROLIDINE DERIVATIVE; SKATOLE; TRYPTAMINE; UPSTREAM STIMULATORY FACTOR 1; UPSTREAM STIMULATORY FACTOR 2;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL STRESS; ENDOPLASMIC RETICULUM STRESS; ENZYME INDUCTION; ENZYME SUBSTRATE; GENE EXPRESSION; HOMEOSTASIS; HUMAN; LIVER CELL DAMAGE; LIVER METABOLISM; LIVER TOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; XENOBIOTIC METABOLISM;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; ENERGY METABOLISM; ENZYME INDUCTION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEME; HOMEOSTASIS; HUMANS; LIPID METABOLISM; LIVER; OXIDATION-REDUCTION; PORPHYRINS; PYRAZOLES; RNA PROCESSING, POST-TRANSCRIPTIONAL; STRESS, PHYSIOLOGICAL; TRANSCRIPTION FACTORS; XENOBIOTICS;

EID: 79952797177     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011795016845     Document Type: Article

References (154)

1. Camus, A. M.; Geneste, O.; Honkakoski, P.; Bereziat, J. C.; Henderson, C. J.; Wolf, C. R.; Bartsch, H.; Lang, M. A. High variability of nitrosamine metabolism among individuals: Role of cytochromes P450 2A6 and 2E1 in the dealkylation of Nnitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol. Carcinog., 1993, 7(4), 268-275. (Pubitemid 23200893)
2. Kirby, G. M.; Chemin, I.; Montesano, R.; Chisari, F. V.; Lang, M. A.; Wild, C. P. Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol. Carcinog., 1994, 11(2), 74-80. (Pubitemid 24343578)
3. Siu, E. C.; Wildenauer, D. B.; Tyndale, R. F. Nicotine selfadministration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl), 2006, 184(3-4), 401-408. (Pubitemid 43255856)
4. Felicia, N. D.; Rekha, G. K.; Murphy, S. E. Characterization of cytochrome P450 2A4 and 2A5-catalyzed 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone (NNK) metabolism. Arch. Biochem. Biophys., 2000, 384(2), 418-424. (Pubitemid 32012820)
5. Genter, M. B.; Liang, H. C.; Gu, J.; Ding, X.; Negishi, M.; McKinnon, R. A.; Nebert, D. W. Role of CYP2A5 and 2G1 in acetaminophen metabolism and toxicity in the olfactory mucosa of the Cyp1a2(-/-) mouse. Biochem. Pharmacol., 1998, 55(11), 1819-1826. (Pubitemid 28305264)
6. Kirby, G. M.; Batist, G.; Alpert, L.; Lamoureux, E.; Cameron, R. G.; Alaoui-Jamali, M. A. Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol. Pathol., 1996, 24(4), 458-467. (Pubitemid 26274855)
7. Abu-Bakar, A.; Moore, M. R.; Lang, M. A. Evidence for induced microsomal bilirubin degradation by cytochrome P450 2A5. Biochem. Pharmacol., 2005, 70(10), 1527-1535. (Pubitemid 41483463)
8. Zhou, X.; Zhuo, X.; Xie, F.; Kluetzman, K.; Shu, Y. Z.; Humphreys, W. G.; Ding, X. Role of CYP2A5 in the clearance of nicotine and cotinine: Insights from studies on a Cyp2a5-null mouse model. J. Pharmacol. Exp. Ther., 2010, 332(2), 578-587.
9. Kojo, A.; Viitala, P.; Pasanen, M.; Pelkonen, O.; Raunio, H.; Juvonen, R. Induction of CYP2A5 by pyrazole and its derivatives in mouse primary hepatocytes. Arch. Toxicol., 1998, 72(6), 336-341. (Pubitemid 28261449)
10. Juvonen, R. O.; Kaipainen, P. K.; Lang, M. A. Selective induction of coumarin 7-hydroxylase by pyrazole in D2 mice. Eur. J. Biochem., 1985, 152(1), 3-8. (Pubitemid 16248758)
11. Camus-Randon, A. M.; Raffalli, F.; Bereziat, J. C.; McGregor, D.; Konstandi, M.; Lang, M. A. Liver injury and expression of cytochromes P450: Evidence that regulation of CYP2A5 is different from that of other major xenobiotic metabolizing CYP enzymes. Toxicol. Appl. Pharmacol., 1996, 138(1), 140-148. (Pubitemid 26159604)
12. Pellinen, P.; Stenback, F.; Rautio, A.; Pelkonen, O.; Lang, M.; Pasanen, M. Response of mouse liver coumarin 7-hydroxylase activity to hepatotoxins: Dependence on strain and agent and comparison to other monooxygenases. Naunyn Schmiedebergs Arch Pharmacol, 1993, 348(4), 435-443. (Pubitemid 23297684)
13. Pellinen, P.; Stenback, F.; Raunio, H.; Pelkonen, O.; Pasanen, M. Modification of hepatic cytochrome P450 profile by cocaineinduced hepatotoxicity in DBA/2 mouse. Eur. J. Pharmacol., 1994, 292(1), 57-65.
14. Pellinen, P.; Honkakoski, P.; Stenback, F.; Niemitz, M.; Alhava, E.; Pelkonen, O.; Lang, M. A.; Pasanen, M. Cocaine Ndemethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur. J. Pharmacol., 1994, 270(1), 35-43.
15. Hahnemann, B.; Salonpaa, P.; Pasanen, M.; Maenpaa, J.; Honkakoski, P.; Juvonen, R.; Lang, M. A.; Pelkonen, O.; Raunio, H. Effect of pyrazole, cobalt and phenobarbital on mouse liver cytochrome P-450 2a-4/5 (Cyp2a-4/5) expression. Biochem. J., 1992, 286 ( Pt 1), 289-294.
16. Kocer, Z.; Raunio, H.; Pasanen, M.; Arvela, P.; Raiskila, T.; Honkakoski, P.; Lang, M. A.; Negishi, M.; Pelkonen, O. Comparison between cobalt and pyrazole in the increased expression of coumarin 7-hydroxylase in mouse liver. Biochem. Pharmacol., 1991, 41(3), 462-465.
17. Arvela, P.; Kraul, H.; Stenback, F.; Pelkonen, O. The ceriuminduced liver injury and oxidative drug metabolism in DBA/2 and C57BL/6 mice. Toxicology, 1991, 69(1), 1-9.
18. Salonpaa, P.; Pelkonen, O.; Kojo, A.; Pasanen, M.; Negishi, M.; Raunio, H. Cytochrome P4502A5 expression and inducibility by phenobarbital is modulated by cAMP in mouse primary hepatocytes. Biochem. Biophys Res. Commun., 1994, 205(1), 631-637. (Pubitemid 24381673)
19. Abu-Bakar, A.; Satarug, S.; Marks, G. C.; Lang, M. A.; Moore, M. R. Acute cadmium chloride administration induces hepatic and renal CYP2A5 mRNA, protein and activity in the mouse: Involvement of transcription factor NRF2. Toxicol. Lett., 2004, 148(3), 199-210. (Pubitemid 38369222)
20. Mangoura, S. A.; Strack, A.; Legrum, W.; Netter, K. J. Indium selectively increases the cytochrome P-450 dependent Odealkylation of coumarin derivatives in male mice. Naunyn Schmiedebergs Arch. Pharmacol., 1989, 339(5), 596-602. (Pubitemid 19146325)
21. Lamsa, V.; Levonen, A. L.; Leinonen, H.; Yla-Herttuala, S.; Yamamoto, M.; Hakkola, J. Cytochrome P450 2A5 constitutive expression and induction by heavy metals is dependent on redoxsensitive transcription factor Nrf2 in liver. Chem. Res. Toxicol., 23(5), 977-985.
22. Salonpaa, P.; Kottari, S.; Pelkonen, O.; Raunio, H. Regulation of CYP 2 A 5 induction by porphyrinogenic agents in mouse primary hepatocytes. Naunyn Schmiedebergs Arch. Pharmacol., 1997, 355(1), 8-13. (Pubitemid 27008446)
23. Salonpaa, P.; Krause, K.; Pelkonen, O.; Raunio, H. Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver. Naunyn Schmiedebergs Arch. Pharmacol., 1995, 351(4), 446-452.
24. Viitala, P.; Posti, K.; Lindfors, A.; Pelkonen, O.; Raunio, H. cAMP mediated upregulation of CYP2A5 in mouse hepatocytes. Biochem. Biophys. Res. Commun., 2001, 280(3), 761-767. (Pubitemid 32924495)
25. Cai, Y.; Konishi, T.; Han, G.; Campwala, K. H.; French, S. W.; Wan, Y. J. The role of hepatocyte RXR alpha in xenobiotic-sensing nuclear receptor-mediated pathways. Eur. J. Pharm. Sci., 2002, 15(1), 89-96. (Pubitemid 34136972)
26. Gilmore, W. J.; Kirby, G. M. Endoplasmic reticulum stress due to altered cellular redox status positively regulates murine hepatic CYP2A5 expression. J. Pharmacol. Exp. Ther., 2004, 308(2), 600-608. (Pubitemid 38134222)
27. Donato, M. T.; Viitala, P.; Rodriguez-Antona, C.; Lindfors, A.; Castell, J. V.; Raunio, H.; Gomez-Lechon, M. J.; Pelkonen, O. CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab. Dispos., 2000, 28(11), 1321-1326.
28. Macak-Safranko, Z.; Sobocanec, S.; Saric, A.; Balog, T.; Sverko, V.; Kusic, B.; Marotti, T. Cytochrome P450 gender-related differences in response to hyperoxia in young CBA mice. Exp. Toxicol. Pathol., 2010.
29. Arpiainen, S.; Raffalli-Mathieu, F.; Lang, M. A.; Pelkonen, O.; Hakkola, J. Regulation of the Cyp2a5 gene involves an aryl hydrocarbon receptor-dependent pathway. Mol. Pharmacol., 2005, 67(4), 1325-1333. (Pubitemid 40410433)
30. Sipowicz, M. A.; Chomarat, P.; Diwan, B. A.; Anver, M. A.; Awasthi, Y. C.; Ward, J. M.; Rice, J. M.; Kasprzak, K. S.; Wild, C. P.; Anderson, L. M. Increased oxidative DNA damage and hepatocyte overexpression of specific cytochrome P450 isoforms in hepatitis of mice infected with Helicobacter hepaticus. Am. J. Pathol., 1997, 151(4), 933-941. (Pubitemid 27424302)
31. Montero, R.; Gentile, G. J.; Frederick, L.; McMannis, J.; Murphy, T.; Silva, G.; Blankespoor, H.; Gentile, J. M. Induced expression of CYP2A5 in inflamed trematode-infested mouse liver. Mutagenesis, 1999, 14(2), 217-220. (Pubitemid 29123787)
32. Kirby, G. M.; Pelkonen, P.; Vatanasapt, V.; Camus, A. M.; Wild, C. P.; Lang, M. A. Association of liver fluke (Opisthorchis viverrini) infestation with increased expression of cytochrome P450 and carcinogen metabolism in male hamster liver. Mol. Carcinog., 1994, 11(2), 81-89. (Pubitemid 24343579)
33. Chemin, I.; Takahashi, S.; Belloc, C.; Lang, M. A.; Ando, K.; Guidotti, L. G.; Chisari, F. V.; Wild, C. P. Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model of fulminant hepatitis. Hepatology, 1996, 24(3), 649-656. (Pubitemid 26296011)
34. Chisari, F. V.; Klopchin, K.; Moriyama, T.; Pasquinelli, C.; Dunsford, H. A.; Sell, S.; Pinkert, C. A.; Brinster, R. L.; Palmiter, R. D. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell, 1989, 59(6), 1145-1156. (Pubitemid 20024625)
35. Chomarat, P.; Sipowicz, M. A.; Diwan, B. A.; Fornwald, L. W.; Awasthi, Y. C.; Anver, M. R.; Rice, J. M.; Anderson, L. M.; Wild, C. P. Distinct time courses of increase in cytochromes P450 1A2, 2A5 and glutathione S-transferases during the progressive hepatitis associated with Helicobacter hepaticus. Carcinogenesis, 1997, 18(11), 2179-2190. (Pubitemid 28134746)
36. Thulke-Gross, M.; Hergenhahn, M.; Tilloy-Ellul, A.; Lang, M.; Bartsch, H. Pyrazole-inducible proteins in DBA/2 mouse liver bind with high affinity to the 3'-untranslated regions of the mRNAs of coumarin hydroxylase (CYP2A5) and c-jun. Biochem. J., 1998, 331 ( Pt 2), 473-481.
37. De-Oliveira, A. C.; Carvalho, R. S.; Paixao, F. H.; Tavares, H. S.; Gueiros, L. S.; Siqueira, C. M.; Paumgartten, F. J. Up- and downmodulation of liver cytochrome P450 activities and associated events in two murine malaria models. Malar. J., 9, 81.
38. De-Oliveira, A. C.; Da-Matta, A. C.; Paumgartten, F. J. Plasmodium berghei (ANKA): Infection induces CYP2A5 and 2E1 while depressing other CYP isoforms in the mouse liver. Exp. Parasitol., 2006, 113(4), 256-261. (Pubitemid 44061790)
39. Richardson, T. A.; Sherman, M.; Kalman, D.; Morgan, E. T. Expression of UDP-glucuronosyltransferase isoform mRNAs during inflammation and infection in mouse liver and kidney. Drug Metab. Dispos., 2006, 34(3), 351-353. (Pubitemid 43290891)
40. Jounaidi, Y.; Bonfils, C.; Perin, F.; Negishi, M.; Lange, R. Overexpression of a cytochrome P-450 of the 2a family (Cyp2a-5) in chemically induced hepatomas from female mice. Eur. J. Biochem., 1994, 219(3), 791-798. (Pubitemid 24050947)
41. Kobliakov, V.; Kulikova, L.; Samoilov, D.; Lang, M. A. High expression of cytochrome P450 2a-5 (coumarin 7-hydroxylase) in mouse hepatomas. Mol. Carcinog., 1993, 7(4), 276-280. (Pubitemid 23200894)
42. Cheung, C.; Akiyama, T. E.; Kudo, G.; Gonzalez, F. J. Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1- alpha (HNF1alpha)-deficient mice. Biochem. Pharmacol., 2003, 66(10), 2011-2020. (Pubitemid 37352864)
43. Smith, A. G.; Davies, R.; Dalton, T. P.; Miller, M. L.; Judah, D.; Riley, J.; Gant, T.; Nebert, D. W., Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. EHP Toxicogenomics, 2003, 111(1T), 45-51.
44. Weng, Y.; DiRusso, C. C.; Reilly, A. A.; Black, P. N.; Ding, X. Hepatic gene expression changes in mouse models with liverspecific deletion or global suppression of the NADPH-cytochrome P450 reductase gene. Mechanistic implications for the regulation of microsomal cytochrome P450 and the fatty liver phenotype. J Biol Chem, 2005, 280(36), 31686-31698. (Pubitemid 41291916)
45. Davies, R.; Schuurman, A.; Barker, C. R.; Clothier, B.; Chernova, T.; Higginson, F. M.; Judah, D. J.; Dinsdale, D.; Edwards, R. E.; Greaves, P.; Gant, T. W.; Smith, A. G. Hepatic gene expression in protoporphyic Fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool. Am. J. Pathol., 2005, 166(4), 1041-1053. (Pubitemid 40524429)
46. Su, T.; Ding, X. Regulation of the cytochrome P450 2A genes. Toxicol. Appl. Pharmacol., 2004, 199(3), 285-294. (Pubitemid 39208728)
47. Arpiainen, S.; Lamsa, V.; Pelkonen, O.; Yim, S. H.; Gonzalez, F. J.; Hakkola, J. Aryl hydrocarbon receptor nuclear translocator and upstream stimulatory factor regulate Cytochrome P450 2a5 transcription through a common E-box site. J. Mol. Biol., 2007, 369(3), 640-652. (Pubitemid 46709930)
48. Ulvila, J.; Arpiainen, S.; Pelkonen, O.; Aida, K.; Sueyoshi, T.; Negishi, M.; Hakkola, J. Regulation of Cyp2a5 transcription in mouse primary hepatocytes: Roles of hepatocyte nuclear factor 4 and nuclear factor I. Biochem. J., 2004, 381(Pt 3), 887-894. (Pubitemid 39120500)
49. Abu-Bakar, A.; Lamsa, V.; Arpiainen, S.; Moore, M. R.; Lang, M. A.; Hakkola, J. Regulation of CYP2A5 gene by the transcription factor nuclear factor (erythroid-derived 2)-like 2. Drug Metab. Dispos., 2007, 35(5), 787-794. (Pubitemid 46641550)
50. Cullinan, S. B.; Zhang, D.; Hannink, M.; Arvisais, E.; Kaufman, R. J.; Diehl, J. A. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell. Biol., 2003, 23(20), 7198-7209. (Pubitemid 37211002)
51. Motohashi, H.; Yamamoto, M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med., 2004, 10(11), 549-557. (Pubitemid 39433824)
52. Park, J.; Rho, H. K.; Kim, K. H.; Choe, S. S.; Lee, Y. S.; Kim, J. B., Overexpression of glucose-6-phosphate dehydrogenase is associated with lipid dysregulation and insulin resistance in obesity. Mol. Cell. Biol., 2005, 25(12), 5146-5157. (Pubitemid 40781113)
53. Itoh, K.; Mochizuki, M.; Ishii, Y.; Ishii, T.; Shibata, T.; Kawamoto, Y.; Kelly, V.; Sekizawa, K.; Uchida, K.; Yamamoto, M. Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)- prostaglandin j(2). Mol. Cell. Biol., 2004, 24(1), 36-45. (Pubitemid 38010033)
54. Lee, B. S.; Heo, J.; Kim, Y. M.; Shim, S. M.; Pae, H. O.; Chung, H. T. Carbon monoxide mediates heme oxygenase 1 induction via Nrf2 activation in hepatoma cells. Biochem. Biophys. Res. Commun., 2006, 343(3), 965-972.
55. Buckley, B. J.; Marshall, Z. M.; Whorton, A. R. Nitric oxide stimulates Nrf2 nuclear translocation in vascular endothelium. Biochem. Biophys. Res. Commun., 2003, 307(4), 973-979. (Pubitemid 36871668)
56. Miao, W.; Hu, L.; Scrivens, P. J.; Batist, G. Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: Direct cross-talk between phase I and II drugmetabolizing enzymes. J. Biol. Chem., 2005, 280(21), 20340-20348. (Pubitemid 40776732)
57. Nebert, D. W.; Roe, A. L.; Dieter, M. Z.; Solis, W. A.; Yang, Y.; Dalton, T. P. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem. Pharmacol., 2000, 59(1), 65-85.
58. Tuschl, G.; Hrach, J.; Hewitt, P. G.; Mueller, S. O. Application of short- and long-term hepatocyte cultures to predict toxicities. In Hepatotoxicity: From Genomics to in vitro and in vivo Models, Sahu, S. C., Ed. John Wiley & Sons, Ltd: London, 2007; pp pp 141-174.
59. Phelan, D.; Winter, G. M.; Rogers, W. J.; Lam, J. C.; Denison, M. S. Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin. Arch. Biochem. Biophys., 1998, 357(1), 155-163. (Pubitemid 28402597)
60. Machado, F. S.; Johndrow, J. E.; Esper, L.; Dias, A.; Bafica, A.; Serhan, C. N.; Aliberti, J. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med., 2006, 12(3), 330-334. (Pubitemid 43355082)
61. Heath-Pagliuso, S.; Rogers, W. J.; Tullis, K.; Seidel, S. D.; Cenijn, P. H.; Brouwer, A.; Denison, M. S. Activation of the Ah receptor by tryptophan and tryptophan metabolites. Biochemistry, 1998, 37(33), 11508-11515. (Pubitemid 28388192)
62. Corre, S.; Galibert, M. D. Upstream stimulating factors: Highly versatile stress-responsive transcription factors. Pigment Cell Res., 2005, 18(5), 337-348. (Pubitemid 41360809)
63. Rada-Iglesias, A.; Ameur, A.; Kapranov, P.; Enroth, S.; Komorowski, J.; Gingeras, T. R.; Wadelius, C. Whole-genome maps of USF1 and USF2 binding and histone H3 acetylation reveal new aspects of promoter structure and candidate genes for common human disorders. Genome Res., 2008, 18(3), 380-392. (Pubitemid 351347081)
64. van Deursen, D.; Jansen, H.; Verhoeven, A. J. Glucose increases hepatic lipase expression in HepG2 liver cells through upregulation of upstream stimulatory factors 1 and 2. Diabetologia, 2008, 51(11), 2078-2087.
65. Marmillot, P.; Scovell, W. Enhancement of transcription factor, USF, binding to the adenovirus major late promoter: Effect of dithiothreitol and high mobility group protein-1. Biochim. Biophys. Acta, 1998, 1395(2), 228-236. (Pubitemid 28105731)
66. Chen, D.; Lepar, G.; Kemper, B. A transcriptional regulatory element common to a large family of hepatic cytochrome P450 genes is a functional binding site of the orphan receptor HNF-4. J. Biol. Chem., 1994, 269(7), 5420-5427. (Pubitemid 24239541)
67. Gonzalez, F. J. Regulation of hepatocyte nuclear factor 4 alphamediated transcription. Drug Metab. Pharmacokinet., 2008, 23(1), 2-7.
68. Sladek, F. M., Orphan receptor HNF-4 and liver-specific gene expression. Receptor, 1993, 3(3), 223-232.
69. Stoffel, M.; Duncan, S. A. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc. Natl. Acad. Sci. U S A, 1997, 94(24), 13209-13214. (Pubitemid 27518501)
70. Watts, G. F.; Chan, D. C.; Barrett, P. H.; O'Neill, F. H.; Thompson, G. R. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int. J. Obes. Relat. Metab. Disord., 2003, 27(7), 862-865. (Pubitemid 36819546)
71. Arpiainen, S.; Jarvenpaa, S. M.; Manninen, A.; Viitala, P.; Lang, M. A.; Pelkonen, O.; Hakkola, J. Coactivator PGC-1alpha regulates the fasting inducible xenobiotic-metabolizing enzyme CYP2A5 in mouse primary hepatocytes. Toxicol. Appl. Pharmacol., 2008, 232(1), 135-141.
72. Lin, J.; Yang, R.; Tarr, P. T.; Wu, P. H.; Handschin, C.; Li, S.; Yang, W.; Pei, L.; Uldry, M.; Tontonoz, P.; Newgard, C. B.; Spiegelman, B. M. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell, 2005, 120(2), 261-273. (Pubitemid 40174768)
73. Lavery, D. J.; Lopez-Molina, L.; Margueron, R.; Fleury-Olela, F.; Conquet, F.; Schibler, U.; Bonfils, C. Circadian expression of the steroid 15 alpha-hydroxylase (Cyp2a4) and coumarin 7- hydroxylase (Cyp2a5) genes in mouse liver is regulated by the PAR leucine zipper transcription factor DBP. Mol. Cell. Biol., 1999, 19(10), 6488-6499. (Pubitemid 29441834)
74. Canaple, L.; Rambaud, J.; Dkhissi-Benyahya, O.; Rayet, B.; Tan, N. S.; Michalik, L.; Delaunay, F.; Wahli, W.; Laudet, V. Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock. Mol. Endocrinol., 2006, 20(8), 1715-1727. (Pubitemid 44148079)
75. Rudic, R. D.; McNamara, P.; Curtis, A. M.; Boston, R. C.; Panda, S.; Hogenesch, J. B.; Fitzgerald, G. A. BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol., 2004, 2(11), e377.
76. Foretz, M.; Ancellin, N.; Andreelli, F.; Saintillan, Y.; Grondin, P.; Kahn, A.; Thorens, B.; Vaulont, S.; Viollet, B. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes, 2005, 54(5), 1331-1339. (Pubitemid 40586661)
77. Maglich, J. M.; Stoltz, C. M.; Goodwin, B.; Hawkins-Brown, D.; Moore, J. T.; Kliewer, S. A. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol., 2002, 62(3), 638-646. (Pubitemid 36329382)
78. Rosenfeld, J. M.; Vargas, R., Jr.; Xie, W.; Evans, R. M. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol. Endocrinol., 2003, 17(7), 1268-1282. (Pubitemid 36819950)
79. Konno, Y.; Negishi, M.; Kodama, S. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab. Pharmacokinet., 2008, 23(1), 8-13.
80. Moreau, A.; Vilarem, M. J.; Maurel, P.; Pascussi, J. M. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol. Pharm., 2008, 5(1), 35-41. (Pubitemid 351300032)
81. Roth, A.; Looser, R.; Kaufmann, M.; Blattler, S. M.; Rencurel, F.; Huang, W.; Moore, D. D.; Meyer, U. A. Regulatory cross-talk between drug metabolism and lipid homeostasis: Constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol. Pharmacol., 2008, 73(4), 1282-1289. (Pubitemid 351439210)
82. Timsit, Y. E.; Negishi, M. CAR and PXR: The xenobiotic-sensing receptors. Steroids, 2007, 72(3), 231-246. (Pubitemid 46273513)
83. Aida, K.; Negishi, M. Posttranscriptional regulation of coumarin 7- hydroxylase induction by xenobiotics in mouse liver: MRNA stabilization by pyrazole. Biochemistry, 1991, 30(32), 8041-8045.
84. Tilloy-Ellul, A.; Raffalli-Mathieu, F.; Lang, M. A. Analysis of RNA-protein interactions of mouse liver cytochrome P4502A5 mRNA. Biochem. J., 1999, 339 ( Pt 3), 695-703. (Pubitemid 29243534)
85. Raffalli-Mathieu, F.; Glisovic, T.; Ben-David, Y.; Lang, M. A., Heterogeneous nuclear ribonucleoprotein A1 and regulation of the xenobiotic-inducible gene Cyp2a5. Mol. Pharmacol., 2002, 61(4), 795-799. (Pubitemid 34273159)
86. Ford, L. P.; Wright, W. E.; Shay, J. W. A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation. Oncogene, 2002, 21(4), 580-583. (Pubitemid 34146257)
87. Guil, S.; Long, J. C.; Caceres, J. F. hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Mol. Cell. Biol., 2006, 26(15), 5744-5758. (Pubitemid 44134331)
88. Allemand, E.; Guil, S.; Myers, M.; Moscat, J.; Caceres, J. F.; Krainer, A. R. Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proc. Natl. Acad. Sci. U S A, 2005, 102(10), 3605-3610. (Pubitemid 40354658)
89. Glisovic, T.; Ben-David, Y.; Lang, M. A.; Raffalli-Mathieu, F. Interplay between hnRNP A1 and a cis-acting element in the 3' UTR of CYP2A5 mRNA is central for high expression of the gene. FEBS Lett., 2003, 535(1-3), 147-152. (Pubitemid 36126371)
90. Glisovic, T.; Soderberg, M.; Christian, K.; Lang, M.; Raffalli- Mathieu, F. Interplay between transcriptional and posttranscriptional regulation of Cyp2a5 expression. Biochem. Pharmacol., 2003, 65(10), 1653-1661. (Pubitemid 36577278)
91. Gilmore, W. J.; Hartmann, G.; Piquette-Miller, M.; Marriott, J.; Kirby, G. M. Effects of lipopolysaccharide-stimulated inflammation and pyrazole-mediated hepatocellular injury on mouse hepatic Cyp2a5 expression. Toxicology, 2003, 184(2-3), 211-226. (Pubitemid 36009302)
92. Siewert, E.; Bort, R.; Kluge, R.; Heinrich, P. C.; Castell, J.; Jover, R. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology, 2000, 32(1), 49-55. (Pubitemid 30432365)
93. Lieber, C. S.; Rubin, E.; DeCarli, L. M. Hepatic microsomal ethanol oxidizing system (MEOS): Differentiation from alcohol dehydrogenase and NADPH oxidase. Biochem. Biophys. Res. Commun., 1970, 40(4), 858-865.
94. Alam, J.; Shibahara, S.; Smith, A. Transcriptional activation of the heme oxygenase gene by heme and cadmium in mouse hepatoma cells. J. Biol. Chem., 1989, 264(11), 6371-6375. (Pubitemid 19106717)
95. Beyersmann, D.; Hechtenberg, S. Cadmium, gene regulation, and cellular signalling in mammalian cells. Toxicol. Appl. Pharmacol., 1997, 144(2), 247-261. (Pubitemid 27268346)
96. Gottschling, B. C.; Maronpot, R. R.; Hailey, J. R.; Peddada, S.; Moomaw, C. R.; Klaunig, J. E.; Nyska, A. The role of oxidative stress in indium phosphide-induced lung carcinogenesis in rats. Toxicol. Sci., 2001, 64(1), 28-40. (Pubitemid 33062185)
97. Valko, M.; Morris, H.; Cronin, M. T. Metals, toxicity and oxidative stress. Curr. Med. Chem., 2005, 12(10), 1161-1208.
98. Beddowes, E. J.; Faux, S. P.; Chipman, J. K. Chloroform, carbon tetrachloride and glutathione depletion induce secondary genotoxicity in liver cells via oxidative stress. Toxicology, 2003, 187(2-3), 101-115. (Pubitemid 36423306)
99. Denk, G. U.; Soroka, C. J.; Mennone, A.; Koepsell, H.; Beuers, U.; Boyer, J. L. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology, 2004, 39(5), 1382-1389. (Pubitemid 38569060)
100. Devi, B. G.; Chan, A. W. Cocaine-induced peroxidative stress in rat liver: Antioxidant enzymes and mitochondria. J. Pharmacol. Exp. Ther., 1996, 279(1), 359-366. (Pubitemid 27166932)
101. Hagen, T. M.; Huang, S.; Curnutte, J.; Fowler, P.; Martinez, V.; Wehr, C. M.; Ames, B. N.; Chisari, F. V. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc. Natl. Acad. Sci. U S A, 1994, 91(26), 12808-12812.
102. Biaglow, J. E.; Varnes, M. E.; Roizen-Towle, L.; Clark, E. P.; Epp, E. R.; Astor, M. B.; Hall, E. J. Biochemistry of reduction of nitro heterocycles. Biochem. Pharmacol., 1986, 35(1), 77-90. (Pubitemid 16161368)
103. Clejan, L. A.; Cederbaum, A. I. Oxidation of pyrazole by reconstituted systems containing cytochrome P-450 IIE1. Biochim. Biophys. Acta, 1990, 1034(2), 233-237. (Pubitemid 20157833)
104. Rahman, I. Regulation of nuclear factor-kappa B, activator protein- 1, and glutathione levels by tumor necrosis factor-alpha and dexamethasone in alveolar epithelial cells. Biochem. Pharmacol., 2000, 60(8), 1041-1049.
105. Banhegyi, G.; Baumeister, P.; Benedetti, A.; Dong, D.; Fu, Y.; Lee, A. S.; Li, J.; Mao, C.; Margittai, E.; Ni, M.; Paschen, W.; Piccirella, S.; Senesi, S.; Sitia, R.; Wang, M.; Yang, W. Endoplasmic reticulum stress. Ann. N. Y. Acad. Sci., 2007, 1113, 58-71. (Pubitemid 350015006)
106. Halleck, M. M.; Holbrook, N. J.; Skinner, J.; Liu, H.; Stevens, J. L. The molecular response to reductive stress in LLC-PK1 renal epithelial cells: Coordinate transcriptional regulation of gadd153 and grp78 genes by thiols. Cell Stress Chaperones, 1997, 2(1), 31-40. (Pubitemid 27170404)
107. Nichols, K. D.; Kirby, G. M. Expression of cytochrome P450 2A5 in a glucose-6-phosphate dehydrogenase-deficient mouse model of oxidative stress. Biochem. Pharmacol., 2008, 75(5), 1230-1239.
108. Cribb, A. E.; Peyrou, M.; Muruganandan, S.; Schneider, L. The endoplasmic reticulum in xenobiotic toxicity. Drug Metab. Rev., 2005, 37(3), 405-442. (Pubitemid 41434157)
109. Lewis, M. D.; Roberts, B. J. Role of CYP2E1 activity in endoplasmic reticulum ubiquitination, proteasome association, and the unfolded protein response. Arch. Biochem. Biophys., 2005, 436(2), 237-245. (Pubitemid 40576264)
110. Lu, Y.; Zhuge, J.; Wu, D.; Cederbaum, A. I. Ethanol-induction of Cytochrome P450 2A5: Permissive Role for CYP2E1. Drug Metab. Dispos.
111. Tetri, S.; Ruhanen, M.; Viitala, P.; Pelkonen, O.; Pasanen, M.; Raunio, H. Lack of association between CYP2A5 induction and apoptosis in mouse primary hepatocytes. Biochem. Pharmacol., 2002, 63(3), 429-435. (Pubitemid 34169723)
112. Reichard, J. F.; Sartor, M. A.; Puga, A. BACH1 is a specific repressor of HMOX1 that is inactivated by arsenite. J. Biol. Chem., 2008, 283(33), 22363-22370.
113. Jover, R.; Hoffmann, F.; Scheffler-Koch, V.; Lindberg, R. L. Limited heme synthesis in porphobilinogen deaminase-deficient mice impairs transcriptional activation of specific cytochrome P450 genes by phenobarbital. Eur. J. Biochem., 2000, 267(24), 7128-7137. (Pubitemid 32009454)
114. Nichols, K. D.; Kirby, G. M. Microarray analysis of hepatic gene expression in pyrazole-mediated hepatotoxicity: Identification of potential stimuli of Cyp2a5 induction. Biochem. Pharmacol., 2008, 75(2), 538-551. (Pubitemid 350298476)
115. Lu, Y.; Gong, P.; Cederbaum, A. I. Pyrazole induced oxidative liver injury independent of CYP2E1/2A5 induction due to Nrf2 deficiency. Toxicology, 2008, 252(1-3), 9-16.
116. Imaoka, S.; Hashizume, T.; Funae, Y. Localization of rat cytochrome P450 in various tissues and comparison of arachidonic acid metabolism by rat P450 with that by human P450 orthologs. Drug Metab. Pharmacokinet., 2005, 20(6), 478-484.
117. Rifkind, A. B.; Lee, C.; Chang, T. K.; Waxman, D. J. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: Regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch. Biochem. Biophys., 1995, 320(2), 380-389.
118. Niemela, O.; Parkkila, S.; Juvonen, R. O.; Viitala, K.; Gelboin, H. V.; Pasanen, M. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J. Hepatol., 2000, 33(6), 893-901.
119. Xie, Q.; Zhang, Q. Y.; Zhang, Y.; Su, T.; Gu, J.; Kaminsky, L. S.; Ding, X., Induction of mouse CYP2J by pyrazole in the eye, kidney, liver, lung, olfactory mucosa, and small intestine, but not in the heart. Drug Metab. Dispos., 2000, 28(11), 1311-1316.
120. DeBarber, A. E.; Bleyle, L. A.; Roullet, J. B.; Koop, D. R., Omegahydroxylation of farnesol by mammalian cytochromes p450. Biochim. Biophys. Acta, 2004, 1682(1-3), 18-27. (Pubitemid 38670531)
121. Adas, F.; Salaun, J. P.; Berthou, F.; Picart, D.; Simon, B.; Amet, Y. Requirement for omega and (omega;-1)-hydroxylations of fatty acids by human cytochromes P450 2E1 and 4A11. J. Lipid Res., 1999, 40(11), 1990-1997. (Pubitemid 29523425)
122. Long, Y. C.; Zierath, J. R. AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest., 2006, 116(7), 1776-1783. (Pubitemid 44033297)
123. Rencurel, F.; Stenhouse, A.; Hawley, S. A.; Friedberg, T.; Hardie, D. G.; Sutherland, C.; Wolf, C. R. AMP-activated protein kinase mediates phenobarbital induction of CYP2B gene expression in hepatocytes and a newly derived human hepatoma cell line. J. Biol. Chem., 2005, 280(6), 4367-4373. (Pubitemid 41741356)
124. Hawley, S. A.; Boudeau, J.; Reid, J. L.; Mustard, K. J.; Udd, L.; Makela, T. P.; Alessi, D. R.; Hardie, D. G. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol., 2003, 2(4), 28.
125. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M. F.; Goodyear, L. J.; Moller, D. E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 2001, 108(8), 1167-1174. (Pubitemid 32995375)
126. Onica, T.; Nichols, K.; Larin, M.; Ng, L.; Maslen, A.; Dvorak, Z.; Pascussi, J. M.; Vilarem, M. J.; Maurel, P.; Kirby, G. M. Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter. Mol. Pharmacol., 2008, 73(2), 451-460. (Pubitemid 351159215)
127. Geneste, O.; Raffalli, F.; Lang, M. A. Identification and characterization of a 44 kDa protein that binds specifically to the 3'-untranslated region of CYP2a5 mRNA: Inducibility, subcellular distribution and possible role in mRNA stabilization. Biochem. J., 1996, 313 ( Pt 3), 1029-1037.
128. Thunell, S. (Far) Outside the box: Genomic approach to acute porphyria. Physiol. Res., 2006, 55 Suppl 2, S43-66.
129. Diaz, G. J.; Squires, E. J. Metabolism of 3-methylindole by porcine liver microsomes: Responsible cytochrome P450 enzymes. Toxicol. Sci., 2000, 55(2), 284-292. (Pubitemid 30353235)
130. Chen, G.; Cue, R. A.; Lundstrom, K.; Wood, J. D.; Doran, O. Regulation of CYP2A6 protein expression by skatole, indole, and testicular steroids in primary cultured pig hepatocytes. Drug Metab. Dispos., 2008, 36(1), 56-60.
131. Messina, E. S.; Tyndale, R. F.; Sellers, E. M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther., 1997, 282(3), 1608-1614. (Pubitemid 27408347)
132. Zhou, X.; Zhuo, X.; Xie, F.; Kluetzman, K.; Shu, Y. Z.; Humphreys, W. G.; Ding, X. Role of CYP2A5 in the clearance of nicotine and cotinine: Insights from studies on a Cyp2a5-null mouse model. J. Pharmacol. Exp. Ther., 332(2), 578-587.
133. Malaiyandi, V.; Sellers, E. M.; Tyndale, R. F. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin. Pharmacol. Ther., 2005, 77(3), 145-158. (Pubitemid 40269130)
134. Higashi, E.; Nakajima, M.; Katoh, M.; Tokudome, S.; Yokoi, T. Inhibitory effects of neurotransmitters and steroids on human CYP2A6. Drug Metab. Dispos., 2007, 35(4), 508-514. (Pubitemid 46513276)
135. Kimura, M.; Yamazaki, H.; Fujieda, M.; Kiyotani, K.; Honda, G.; Saruwatari, J.; Nakagawa, K.; Ishizaki, T.; Kamataki, T. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7- dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab. Dispos., 2005, 33(9), 1361-1366. (Pubitemid 41196980)
136. Smith, B. D.; Sanders, J. L.; Porubsky, P. R.; Lushington, G. H.; Stout, C. D.; Scott, E. E. Structure of the human lung cytochrome P450 2A13. J. Biol. Chem., 2007, 282(23), 17306-17313. (Pubitemid 47093207)
137. Oakes, G. H.; Bend, J. R. Global changes in gene regulation demonstrate that unconjugated bilirubin is able to upregulate and activate select components of the endoplasmic reticulum stress response pathway. J. Biochem. Mol. Toxicol., 24(2), 73-88.
138. Ryter, S. W.; Alam, J.; Choi, A. M. Heme oxygenase-1/carbon monoxide: From basic science to therapeutic applications. Physiol. Rev., 2006, 86(2), 583-650.
139. Burgess, A.; Li, M.; Vanella, L.; Kim, D. H.; Rezzani, R.; Rodella, L.; Sodhi, K.; Canestraro, M.; Martasek, P.; Peterson, S. J.; Kappas, A.; Abraham, N. G. Adipocyte heme oxygenase-1 induction attenuates metabolic syndrome in both male and female obese mice. Hypertension, 2010, 56(6), 1124-1130.
140. Ndisang, J. F.; Lane, N.; Syed, N.; Jadhav, A. Up-regulating the heme oxygenase system with hemin improves insulin sensitivity and glucose metabolism in adult spontaneously hypertensive rats. Endocrinology, 2010, 151(2), 549-560.
141. Sodhi, K.; Inoue, K.; Gotlinger, K. H.; Canestraro, M.; Vanella, L.; Kim, D. H.; Manthati, V. L.; Koduru, S. R.; Falck, J. R.; Schwartzman, M. L.; Abraham, N. G. Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J. Pharmacol. Exp. Ther., 2009, 331(3), 906-916.
142. Was, H.; Dulak, J.; Jozkowicz, A., Heme oxygenase-1 in tumor biology and therapy. Curr. Drug Targets, 2010, 11(12), 1551-1570.
143. Kim, H. P.; Pae, H. O.; Back, S. H.; Chung, S. W.; Woo, J. M.; Son, Y.; Chung, H. T. Heme oxygenase-1 comes back to endoplasmic reticulum. Biochem. Biophys Res. Commun., 2011, 404(1), 1-5.
144. Kapitulnik, J. Bilirubin: An endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol. Pharmacol., 2004, 66(4), 773-779. (Pubitemid 39319447)
145. Seubert, J. M.; Darmon, A. J.; El-Kadi, A. O.; D'Souza, S. J.; Bend, J. R. Apoptosis in murine hepatoma hepa 1c1c7 wild-type, C12, and C4 cells mediated by bilirubin. Mol. Pharmacol., 2002, 62(2), 257-264. (Pubitemid 34804104)
146. Su, T.; He, W.; Gu, J.; Lipinskas, T. W.; Ding, X. Differential xenobiotic induction of CYP2A5 in mouse liver, kidney, lung, and olfactory mucosa. Drug Metab. Dispos., 1998, 26(8), 822-824. (Pubitemid 28376444)
147. Kakizaki, S.; Yamazaki, Y.; Takizawa, D.; Negishi, M. New insights on the xenobiotic-sensing nuclear receptors in liver diseases-CAR and PXR. Curr. Drug Metab., 2008, 9(7), 614-621.
148. Bock, K. W.; Kohle, C. Contributions of the Ah receptor to bilirubin homeostasis and its antioxidative and atheroprotective functions. Biol. Chem., 391(6), 645-653.
149. Hirschfield, G. M.; Alexander, G. J. Gilbert's syndrome: An overview for clinical biochemists. Ann. Clin. Biochem., 2006, 43(Pt 5), 340-343. (Pubitemid 44526531)
150. Kotal, P.; Vitek, L.; Fevery, J. Fasting-related hyperbilirubinemia in rats: The effect of decreased intestinal motility. Gastroenterology, 1996, 111(1), 217-223. (Pubitemid 26226902)
151. Schmid, R.; Hammaker, L. Metabolism and disposition of C14- bilirubin in congenital nonhemolytic jaundice. J. Clin. Invest., 1963, 42, 1720-1734.
152. Sinal, C. J.; Bend, J. R. Aryl hydrocarbon receptor-dependent induction of cyp1a1 by bilirubin in mouse hepatoma hepa 1c1c7 cells. Mol. Pharmacol., 1997, 52(4), 590-599. (Pubitemid 27443980)
153. Chowdhury, J. R.; Kondapalli, R.; Chowdhury, N. R. Gunn rat: A model for inherited deficiency of bilirubin glucuronidation. Adv. Vet. Sci. Comp. Med., 1993, 37, 149-173.
154. Kapitulnik, J.; Gonzalez, F. J. Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat. Mol. Pharmacol., 1993, 43(5), 722-725. (Pubitemid 23146270)